Health information company ALR Technologies, Inc. (OTCBB: ALRT) on Monday disclosed the appointment of William S. Smith as Chief Commercial Officer and member of the Board of Directors, effective January 1, 2013.  Smith will oversee sales and marketing, investor relations, public affairs, communications and government affairs, according to a corporate statement.

Previously, Smith spent ten years as Vice President of U.S. Public Affairs and Policy at Pfizer, Inc. (NYSE: PFE), where he was the lead advisor on U.S. policy issues to Pfizer’s U.S. commercial businesses.

Most recently, he was Managing Director of Healthcare at NSI, LLC, a Washington, D.C.-based consulting firm, where Smith advised pharmaceutical, biotechnology and medical device companies, including AstraZeneca PLC (NYSE: AZN), Merck & Co. (NYSE: MRK), Genzyme Corp. (acquired by Sanofit-Aventis (NYSE: SNY) in 2011 for $20.1 billion), MedImmune, Inc. (acquired by AstraZeneca in 2007 for $15.6 billion), and Brussels, Belgium-based global biopharmaceutical company UCB S.A.

Smith also worked in government as a staff member of two Massachusetts Governors, a leadership aide to the Rupublican Leadership in the U.S. House of Representatives and a senior aide in the White House Office of national Drug Control Policy under President George H.W. Bush.

“I am delighted to welcome Mr. Smith to ALR Technologies,” said ALRT chief executive Sidney Chan. “He has deep experience in the healthcare marketplace and he has significant experience building and leading a large organization. As a consultant, he provided ALRT with invaluable strategic counsel on our key markets and business model. As we now enter the commercial phase of our key product, he will build a world class organization to support our growth.”

“I am very excited to join ALR Technologies,” said Mr. Smith. “The company has developed a technology and a business model that is precisely in the space where healthcare is going. The company has huge potential for growth and its future success would represent a great opportunity for patients with diabetes to better control their condition.”

Smith is referencing ALR’s Health-e-Connect system, a web-based patient management platform for medical professionals to improve compliance and adherence to care plans of patients in their homes.  The company has indicated that the system is expandable to manage a wide array of diseases, but is keeping their initial commercialization initiatives focused on diabetes, a chronic disease impacted tens of millions of patients in the United States that has seen exponential diagnosis rates in recent years.

Shares of ALRT closed trading Monday at 3.3 cents.

ALR Technologies (ALRT) Stock Quote and News:

---

Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated three thousand dollars for one month of consultation, journalism and video presentation production services and to manage an investor relations/awareness program by ALR Technologies. Viper has completed prior service agreements with ALRT Technologies with full disclosure listed on our disclaimer/disclosure page.
Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.